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A B S T R A C T
Objective: Anticoagulation therapy with warfarin is recommended for stroke prevention in patients with
atrial ﬁbrillation (AF) or atrial ﬂutter (AFL) whose risks for stroke are high. However, previous studies
suggest that warfarin is markedly underused. This study aims to investigate the incidence and risk
factors of warfarin underutilization in patients with high risk of stroke in Korea.
Methods: This was a cross-sectional study using the data of 2009 from National Patients Sample
compiled by the Health Insurance Review and Assessment Service. Patients with high risk of
thromboembolism were identiﬁed with congestive heart failure, hypertension, age 75 years, diabetes,
and prior stroke (CHADS2) score 2. High-risk patients of bleeding were excluded using Anticoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) score >4. Warfarin and antithrombotic therapy
underutilization were deﬁned and estimated in high-risk patients. Any demographic and clinical factors
associated with warfarin and antithrombotic therapy underutilization were explored using a logistic
regression model.
Results: Of the national patient sample, 15,885 patients were identiﬁed with AF or AFL. Among them, a
total of 8475 patients who had an admission history, CHADS2 2, and ATRIA score 4 were included in
the analysis. From the study sample, warfarin underutilization and antithrombotic therapy
underutilization were estimated to be 64.0% and 20.4%, respectively. Predictors of warfarin
underutilization include female sex, age 80 years, lower CHADS2 score, and insurance type (Medical
Aid program).
Conclusions: A high portion of AF/AFL patients with CHADS2 score 2 were undertreated with warfarin.
As ischemic stroke is one of the leading causes of death in Korea, a more aggressive approach to prevent
stroke in patients with AF/AFL is required.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atrial ﬁbrillation (AF) or atrial ﬂutter (AFL) is a common type of
supraventricular arrhythmia, characterized by irregular and rapid
heartbeat [1]. It was estimated that between 2.7 million and
6.1 million US citizens had AF in 2010, and the prevalence is
expected to rise to between 5.6 and 12 million in 2050 [2]. It was
projected that by 2050 there would be over 1 million patients with
AF in Japan if limited to persistent and permanent type and around* Corresponding author at: Pusan National University, College of Pharmacy,
Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan 609-735, Republic of Korea.
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E-mail address: jenk@pusan.ac.kr (N.K. Je).
http://dx.doi.org/10.1016/j.jjcc.2015.06.013
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights2 million patients with AF if paroxysmal type was included [3]. In
South Korea, the prevalence of AF was estimated to be 0.7% in the
population of older than 40 years and 2.1% in those older than
65 years [4].
The most serious complication of AF/AFL is ischemic stroke,
which can occur at any point in time during the clinical course of
AF/AFL. AF/AFL patients have ﬁve times the risk of stroke
occurrence than non-AF/AFL patients [5]. Therefore, all patients
with any form of AF/AFL should be on antithrombotic therapy to
prevent stroke if there were no compelling contraindications
[6]. Either oral anticoagulation or antiplatelet therapy is recom-
mended for this purpose in accordance to the patient’s risk for
stroke. There are several risk stratiﬁcation systems. Among them
congestive heart failure, hypertension, age 75 years, diabetes,
previous stroke (CHADS2) system is one of the most utilized reserved.
I.-H. Lee et al. / Journal of Cardiology 66 (2015) 475–481476systems because it is simple and well validated [7]. The CHADS2
system assigns 1 point each for congestive heart failure,
hypertension, age 75 years, and diabetes mellitus, and 2 points
for prior stroke, transient ischemic attack (TIA), or thromboembo-
lism [7]. The CHADS2 system can have a number ranging from 0 to
6, with higher risk of thromboembolism represented by a higher
number. The relationship between the CHADS2 score and
thromboembolic rate was investigated in a cohort study. The
thromboembolic rate was estimated at 0.49, 1.52, 2.50, 5.27, 6.02,
and 6.88 per 100 person-years for patients with CHADS2 score of 0,
1, 2, 3, 4, and 5/6, respectively [8]. The American Heart Association/
American Stroke Association (AHA/ASA) guideline recommends
anticoagulation therapy with warfarin for patients with AF of
CHADS2 score 2, and either anticoagulation or antiplatelet
therapy for patients with AF of CHADS2 score equal to 1 [6]. Aspirin
or no treatment is recommended for patients at very low risk
(CHADS2 score = 0). The stroke prevention guideline in Korea also
recommends warfarin for stroke prevention if patients belong to a
high-risk group [9].
Despite the strong evidence of beneﬁts, a number of studies
have shown that warfarin has been underused among patients
who appear to be appropriate candidates for it [10–25]. A
systematic review was conducted with nine studies that utilized
CHADS2 2 to identify high-risk patients for stroke. These studies
reported warfarin treatment levels ranging from 39% to 70%. Seven
out of nine studies reported a treatment level of below 70% [24].
In Korea, stroke is the second leading cause of death after
cancer, and the ﬁrst leading cause of death if organ-based mortality
is considered [26]. Compliance with evidence-based guidelines has
not been widely studied among patients with AF/AFL in the Korean
healthcare setting. This study aims to investigate warfarin
underutilization (WU) in patients with high risks of stroke in
Korea and its contributing factors.
Methods
Study data
For this study, we analyzed the National Patients Sample data
collected by Korean Health Insurance Review and AssessmentFig. 1. Case extraction diagram. HIRA, Health Insurance Review and Assessment Service
congestive heart failure, hypertension, age 75 years, diabetes, previous stroke; ATRIAService from 2009 (HIRA-NPS-2009-0114). The data were
extracted with stratiﬁed and systematic sampling methods,
considering sex and age group among all patients who used
medical services in 2009. HIRA-NPS-2009 contains 13% of patients
who had admission history to health institutions (designated as
inpatients; n = 711,457) and 1% of patients who had no history of
admission (designated as outpatients; n = 404,583) [27]. The
representativeness of HIRA-NPS-2009 was veriﬁed by the HIRA
and ﬁve other medical associations in Korea [27]. The following
data are available in HIRA-NPS: diagnosis, age, sex, insurance type,
institution, medical expenses, operation name, and prescriptions.
Study subjects
We identiﬁed AF/AFL patients in HIRA-NPS-2009 using KCD-5
(Korean version of ICD-10) [28], which is I48. Patients with any
admission history were included in this study (n = 14,695). We
calculated each patient’s CHADS2 score based on patient’s age and
clinical status including congestive heart failure (KCD-5 code: I50,
I110), hypertension (I10, I11, I12, I13), diabetes mellitus (E10, E11,
E12, E13, E14), previous stroke, TIA, or thromboembolism (I63, I74,
G458, G459) using the diagnosis code. Then, we stratiﬁed patients
into three groups according to the risk of thromboembolism: low-
risk group (CHADS2 score = 0); intermediate-risk group (CHADS2
score = 1 point); and high-risk group (CHADS2 score = 2–6 points)
(Fig. 1). For the purpose of reviewing warfarin utilization, we
extracted only the high-risk group. We also calculated each
patient’s Anticoagulation and Risk Factors in Atrial Fibrillation
(ATRIA) score to estimate bleeding risk on warfarin [29,30]. ATRIA
score is simpler than other bleeding risk assessing tools such as
HAS-BLED and HEMORR2HAGES scores [31–33]. To calculate
ATRIA score, laboratory data such as hemoglobin and creatinine
clearance are needed. We used KCD-5 to ﬁnd patients with anemia
or severe renal disease instead of using laboratory values (i.e.
anemia is deﬁned as hemoglobin <13 g/dL in males or <12 g/dL in
females). In this tool, anemia (KCD-5 code: D46, D50-53, D55-61,
D63-64), severe renal disease (I12.0, I13.1, I13.2, N03-05, N18-19,
P96.0, T82.4, Y84.1, Z99.2), age 75 years, prior hemorrhage (I60-
62, K25.0, K25.2, K25.4, K25.6, K92.2), and hypertension (I10–13)
were identiﬁed as risk factors and 3 points for the ﬁrst two factors; NPS, National Patients Sample; AF, atrial ﬁbrillation; AFL, atrial ﬂutter; CHADS2,
, Anticoagulation and Risk Factors in Atrial Fibrillation.
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1 point for the last two factors (prior hemorrhage, and hyperten-
sion) were assigned. High-risk patients of bleeding whose ATRIA
score >4 were excluded. The remaining 8,475 patients were
included in the analysis.
We grouped the study subjects by age: 0–49, 50–59, 60–69, 70–
79, and 80 years or older. Study subjects under 49 years of age were
too small to be separated into several smaller groups. Insurance
coverage included the National Health Insurance (NHI), the
Medical Aid (MedAid) program, and Patriots & Veterans Insurance
Plan. Approximately 97% of the Korean population is covered
through the NHI, and about 3% of population is secured by the
MedAid [34]. The MedAid complements the NHI to provide a more
comprehensive coverage to low-income households.
Warfarin and aspirin underutilization
Patients in the high-risk group (CHADS2 2) and whose ATRIA
score 4 were included in the analysis. We reviewed the
prescription records of the individual patient in the study group
to ﬁnd out if there is any prescription history of aspirin or warfarin
in the year of 2009. For this purpose we used the Korean ingredient
codes for aspirin and warfarin, which were ofﬁcially designated in
the national insurance beneﬁt list. We included all different
strengths of warfarin and aspirin, but only included oral
formulations, such as tablet or capsule.
We operationally deﬁned WU as that the patient had never
been prescribed warfarin; antithrombotic therapy underutiliza-
tion (ATU) as that the patient had been prescribed neither warfarin
nor aspirin in any health institution visit in 2009. The rate of WU
was computed as the proportion of patients who had never been
prescribed warfarin, and the rate of ATU was calculated the
proportion of patients who had never been prescribed any
antithrombotic therapy as follows:
Rate of WU
¼
Number of patients who have not been
prescribed warfarin
Number of patients whose CHADS2 score  2 100
Rate of ATU
¼
Number of patients who have not been prescribed
either warfarin or aspirin
Number of patients whose CHADS2 score  2  100
Statistical analysis
Descriptive statistics of the outcome variables were examined.
To explore the association of any individual, social, and health-
related factors with WU, we performed logistic regression analyses
between underutilization and each explanatory variable. Under-
treatment was assessed in two ways, WU and ATU as shown above.
Explanatory variables included sex and age as individual factors;
insurance coverage as a social factor; and CHADS2 and prior
admission experience as health status. We excluded 24 cases of
Patriots & Veterans Insurance Plan in the regression due to the
small size of that population.
The ﬁnal models were as follows:
Model 1:
Warfarin underutilization ðcoded WU ¼ 1; otherwise ¼ 0Þ
¼ sex þ age group þ insurance coverage þ CHADS2Model 2:
Antithrombotic therapy underutilization ðcoded ATU
¼ 1; otherwise ¼ 0Þ
¼ sex þ age group þ insurance coverage þ CHADS2
To check the goodness-of-ﬁt for models, c-statistics and the
Hosmer–Lemeshow test were carried out. Data analysis was
performed using SAS 9.2 version (SAS Institute Inc., Cary, NC, USA).
Statistical signiﬁcance was set at p < 0.05.
Results
Characteristics of study subjects
HIRA-NPS-2009 contains 25,766,263 medical records of
1,116,040 patients. Among them 15,885 patients were identiﬁed
to have AF/AFL (1.4%). We identiﬁed high-risk patients of stroke
who had CHADS2 score of greater than or equal to 2 with any
admission history to a medical institution during the year
2009. Then, we excluded patients at increased risk of bleeding
using ATRIA score. Twenty-two percent of patients were identiﬁed
as inappropriate candidates for warfarin (Fig. 1). This is a larger
contraindication rate than previously reported against warfarin
therapy [35–37].
The prevalence of each component in CHADS2 score was
identiﬁed as 47.2% for congestive heart failure, 90.9% for
hypertension, 35.4% for age 75 years, 64.1% for diabetes mellitus,
and 45.6% for prior stroke, TIA, or thromboembolism. The mean age
of the study population was 69.1 years and the proportion of
female patients was 48.6% (Table 1). Most patients were covered by
the National Health Insurance (87.2%).
Warfarin underutilization and antithrombotic therapy
underutilization
The overall WU and ATU among high-risk patients for stroke
were estimated to be 64.0% and 20.4%, respectively (Fig. 2). Women
had higher WU (Table 2). While WU was highest in patients over
80 years old, ATU was highest in patients younger than 50 years
old. Both WU and ATU were decreased with increasing CHADS2
score. The types of insurance also inﬂuenced WU and ATU. The
beneﬁciaries of MedAid were identiﬁed to have higher underutili-
zation in both warfarin and antithrombotic therapy.
Predictors of high warfarin underutilization and antithrombotic
therapy underutilization
The ﬁndings from our logistic regression analysis showed that
the CHADS2 scores had a consistent and directional relationship
with both WU and ATU (Table 3). The lower CHADS2 score was
associated with the higher odds of underutilization both in
warfarin and antithrombotic therapy. Those with the CHADS2
score 2 had 4.09 and 3.61 times greater odds of WU and ATU,
respectively (p < 0.0001). A similar pattern was observed in other
groups by the CHADS2 score but with slightly lower odds.
Groups by age showed a monotonous ﬁgure. Compared to those
of 80 years or older, the odds of underutilization were nearly half in
all age groups except the age group of younger than 50 who had
1.31 times greater odds of WU (p = 0.012). The MedAid plan was
associated with about 1.39 and 1.34 times greater odds of WU and
ATU, respectively (p < 0.0001). Women were more likely to
underutilize warfarin while the odds ratio of underutilization
was relatively small (OR = 1.27, p < 0.0001).
Table 1
Demographic characteristics (N = 8475).
0–49 50–59 60–69 70–79 80 Total (%)
Sex
Men 409 (4.8%) 678 (8.0%) 1213 (14.3%) 1413 (16.7%) 642 (7.6%) 4355 (51.4%)
Women 205 (2.4%) 338 (4.0%) 935 (11.0%) 1655 (19.5%) 987 (11.6%) 4120 (48.6%)
Insurance
NHI 524 (6.2%) 885 (10.4%) 1923 (22.7%) 2663 (31.4%) 1393 (16.4%) 7388 (87.2%)
MedAid 90 (1.1%) 131 (1.5%) 213 (2.5%) 396 (4.7%) 233 (2.7%) 1063 (12.5%)
PVI 0 (0%) 0 (0%) 12 (0.1%) 9 (0.1%) 3 (0%) 24 (0.3%)
CHADS2
2 344 (4.1%) 493 (5.8%) 856 (10.1%) 822 (9.7%) 294 (3.5%) 2809 (33.1%)
3 148 (1.7%) 268 (3.2%) 555 (6.5%) 856 (10.1%) 464 (5.5%) 2291 (27.0%)
4 88 (1.0%) 182 (2.1%) 520 (6.1%) 708 (8.4%) 360 (4.2%) 1858 (21.9%)
5 34 (0.4%) 73 (0.9%) 217 (2.6%) 513 (6.1%) 323 (3.8%) 1160 (13.7%)
6 0 (0%) 0 (0%) 0 (0%) 169 (2.0%) 188 (2.2%) 357 (4.2%)
Total (%) 614 (7.2%) 1016 (12%) 2148 (25.3%) 3068 (36.2%) 1629 (19.2%) 8475 (100%)
NHI, National Health Insurance; MedAid, Medical Aid Plan; PVI, Patriots & Veterans Insurance; CHADS2, congested heart failure, hypertension, age 75, diabetes mellitus,
stroke (or transient ischemic attack).
I.-H. Lee et al. / Journal of Cardiology 66 (2015) 475–481478Discussion
This study suggests that WU is considerably high (64.0%) in
South Korea. In the USA, Glazer et al. analyzed the proportion of
patients with AF receiving warfarin or aspirin during the 6-monthA
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Table 2
Warfarin underutilization and antithrombotic therapy underutilization (N = 8475).
Aspirin
only users
Warfarin
only users
Mixed
users
Non-aspirin-
non-warfarin users
Warfarin
underutilization (%)
Antithrombotic therapy
underutilization (%)
Overall 3693 1262 1790 1730 64.0 20.4
Sex
Men 1910 625 994 826 62.8 19.0
Women 1783 637 796 904 65.2 21.9
Age
0–49 187 108 106 213 65.1 34.7
50–59 414 170 216 216 62.0 21.3
60–69 936 313 516 383 61.4 17.8
70–79 1354 484 692 538 61.7 17.5
80 802 187 260 380 72.6 23.3
Insurance
NHI 3216 1118 1596 1458 63.3 19.7
MedAid 464 141 191 267 68.8 25.1
PVI 13 3 3 5 75.0 20.8
CHADS2
2 1256 373 407 773 72.2 27.5
3 1026 366 426 473 65.4 20.6
4 813 270 471 304 60.1 16.4
5 448 201 367 144 51.0 12.4
6 150 52 119 36 52.1 10.1
NHI, National Health Insurance; MedAid, Medical Aid Plan; PVI, Patriots & Veterans Insurance; CHADS2, congested heart failure, hypertension, age 75, diabetes mellitus,
stroke (or transient ischemic attack).
Table 3
Adjusted odds ratios and 95% conﬁdence intervals from multivariate logistic regression on the underutilization of warfarin and antithrombotic therapy.a
Explanatory variable Warfarin underutilization Antithrombotic therapy underutilization
Adj. OR 95% CI p value Adj. OR 95% CI p value
Sex
Men (R)
Women 1.27 1.14–1.42 <0.0001 1.09 1.00–1.20 0.0617
Age (years)
80 (R)
70–79 0.63 0.54–0.74 <0.0001 0.54 0.47–0.62 <0.0001
60–69 0.58 0.49–0.69 <0.0001 0.47 0.40–0.54 <0.0001
50–59 0.69 0.57–0.85 0.0003 0.45 0.37–0.53 <0.0001
0–49 1.31 1.06–1.63 0.012 0.49 0.39–0.60 <0.0001
Insurance coverage
NHI (R)
MedAid 1.39 1.19–1.62 <0.0001 1.34 1.16–1.55 <0.0001
CHADS2
6 (R)
5 1.44 0.97–2.12 0.0686 1.19 0.93–1.52 0.1643
4 2.11 1.45–3.05 <0.0001 1.91 1.51–2.43 <0.0001
3 2.71 1.88–3.91 <0.0001 2.38 1.88–3.01 <0.0001
2 4.09 2.84–5.89 <0.0001 3.61 2.84–4.58 <0.0001
c-Statistic 0.633 0.620
p value of Hosmer and Lemeshow test 0.5906 0.0983
(R), reference; CHADS2, congested heart failure, hypertension, age 75, diabetes mellitus, stroke (or transient ischemic attack); Adj. OR, adjust odds ratio; CI, conﬁdence
interval; NHI, National Health Insurance; MedAid, Medical Aid Plan.
a Excluded 24 cases of Patriots & Veterans Insurance (PVI) Plan, thus N = 8451 for the regression analysis.
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[11]. Although direct comparison of our study with the previous
studies is not feasible, due to the differences in the deﬁnitions of
WU along with study subjects and design, WU is a common and
persistent issue in current clinical practice.
We found that age 80 years and female sex were strong
predictors of WU, which is in accord with previous studies
[23,38,39]. Gage et al. [23] conducted chart reviews of 597 Medi-
care beneﬁciaries from Missouri hospitals from 1993 to 1996 and
identiﬁed advanced age as a WU factor, in addition to female
gender and rural residency. Bajorek et al. [38] conducted a
retrospective audit of medical records of inpatients aged 65 years
and older with AF from a hospital in Sydney and measured the
proportion of patients prescribed antithrombotic therapy upon
discharge. In this study, patients aged 80 years or older were foundto be less likely to receive warfarin therapy compared to those aged
younger than 80 years. Friberg et al. [39] reported that the
frequency of warfarin use markedly dropped in patients above the
age of 80 years.
Unlike the previous studies we found that the patients younger
than 50 years are less likely to use warfarin to prevent stroke. One
possible explanation for this tendency is that patients of this age
group include those in their 40s who are arguably in Korea the
most actively involved in social and economic activities; therefore,
warfarin therapy requiring regular monitoring is quite demanding
and cumbersome.
The types of insurance were identiﬁed as another strong
predictor for WU and ATU in our study. South Korea runs two
major health insurance plans: the NHI covers about 97% of the
whole population and the MedAid program is a more generous ‘aid’
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the MedAid program are about 3% of the population in 2010s and
the majority of them are in the lowest-income class in society
[34]. Thus, our ﬁnding that such a socially disadvantaged group
had higher WU and ATU may raise an equity issue. In the USA,
Wang et al. [40] reported that insurance status was the single
factor associated with health care access disparities. Medicaid
beneﬁciaries had around 3.4 times higher odds of being unable to
get medical care and 2.2 times higher odds of being unable to get
dental care [40]. Although South Korea has a medical aid system
more generous to vulnerable populations, this may not be enough
to secure their access to necessary healthcare needs.
CHADS2 score was found to have a strong relationship with WU
in the logistic regression, although the patients with lower CHADS2
score still need to take warfarin if they belong to a high-risk group.
What makes physicians reluctant to prescribe warfarin? There
are substantial challenges related to warfarin use. If a patient’s
international normalized ratio (INR) deviates outside of the
therapeutic range (preferred 2–3), the patient will be confronted
with the risk of stroke or bleeding complications [41–43]. Also,
warfarin interacts with numerous medications, herbs, and foods
[44]. Therefore, INR value should be monitored on a regular basis,
which incurs costs. A systematic review of surveys was conducted
by Pugh et al. [20] to identify physician’s attitudes regarding WU.
This study identiﬁed patients’ ability to comply with treatment as
well as advanced age, increased bleeding risk, previous bleeds, fall
risk, and co-morbidities as inﬂuencing factors. As expected,
patients’ ability to comply may not be easily achieved solely by
physicians’ individual efforts. Ingelgard et al. [45] identiﬁed
barriers to prescribing warfarin using a questionnaire of 30 US
physicians developed and reviewed by an expert panel, and they
concurred. Patient factors, such as poor adherence to therapy or
unwillingness to undergo repeat testing, were identiﬁed as the top
ranked reasons.
With such regard, multi-faceted strategies are called for to
reduce WU. Therapeutic strategies may include the following: ﬁrst,
pharmacist interventions have been shown to be beneﬁcial in
enhancing the utilization of warfarin. One retrospective study
demonstrated that a pharmacist-initiated intervention signiﬁcant-
ly improved the prescribing and planning for antithrombotic
therapy in patients with AF [46]. The intervention is composed of a
review and assessment of antithrombotic prescription at the time
of discharge by a pharmacist. Second, a simple software package
tool, such as the Guidance on Risk Assessment and Stroke
Prevention in Atrial Fibrillation (GRASP AF), has been introduced
to physicians in order to identify patients with AF who may be
candidates for prevention with oral anticoagulation on the basis of
their stroke risk proﬁle [47]. These tools could increase the
likelihood of oral anticoagulation prescription, avoid the con-
sequences of stroke, and decrease the overall rate of stroke. Several
new oral anticoagulants (NOACs) have been developed and these
may provide potential advantages over warfarin, including rapid
onset and offset, absence of dietary interactions with vitamin K,
and fewer drug interactions [48]. The more predictable anticoagu-
lant effects of the NOACs allow the use of ﬁxed doses without the
need for routine monitoring. The favorable effects of NOACs, both
in their efﬁcacy and safety, have been shown to be consistent in AF
patients with high risk for both ischemic and bleeding events [49].
Many clinicians are more concerned about hemorrhagic risk of
anticoagulants than beneﬁts of stroke prevention. Magnetic
resonance imaging screening for patients with AF in order to
detect potential risk for intracerebral hemorrhage has been
suggested as another appealing method [50].
We are aware of some limitations of this study. We employed
claims data, which brought both strength and weakness to our
study. While it helped us to have a representative sample, it did notprovide patient-level clinical data that might allow us to identify
contraindications to warfarin or types of AF. Some studies reported
that types of AF could inﬂuence the use of warfarin [39,51]. Friberg
et al. found that patients with paroxysmal AF were treated less
with warfarin than patients with permanent AF [39]. Akao et al.
reported the same phenomenon in all CHADS2 subclasses [51]. We
were unable to consider this factor in the present analysis.
We deﬁned WU and ATU as having not been prescribed any
warfarin or antithrombotic agents at all. In consequence,
underutilization due to poor adherence of drug use or inappropri-
ate INR adjustment was not considered in this study. Thus, our
estimation could be underestimated.
This is the ﬁrst study with a large cohort showing that many
patients with AF/AFL are at increased risk of stroke due to
underutilization of antithrombotic therapy in South Korea. From a
clinical perspective, several questions remain unanswered. Future
study is required to warrant any practice change with antic-
oagulation therapy for high-risk patients with AF with available
NOACs. The main interest of our study was to explore the
underutilization of antithrombotic agents for stroke prevention.
Therefore, we did not pay much attention to a group of patients
who may have been over-treated. However, the issue of over-
treatment has to be investigated in the near future.
Conclusion
Our study demonstrates that a large population of AF/AFL
patients may fail to get adequate stroke prevention in South Korea.
This tendency is more profound in the elderly patients or the
socially disadvantaged group of patients. A more aggressive
approach for these subgroups to get optimal antithrombotic
therapy is warranted.
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